An advancing area of cardiovascular-focused drug development – targeting lipoprotein(a), or Lp(a), to reduce risk of atherosclerotic cardiovascular disease (ASCVD) – is shaping up to be a competitive one dominated by big pharmas, and siRNA developer Silence Therapeutics plc would welcome a larger partner to advance its Lp(a) program zerlasiran into Phase III.
Silence Open To A Partner But Ready To Go It Alone On Lp(a) Drug
Rivals Novartis and Amgen are already in Phase III with Lp(a) drugs
The company said it has the financing to move forward with a Phase III program for zerlasiran in patients with high lipoprotein(a) at high risk of atherosclerotic cardiovascular disease.
